Key clinical point: The biologic drug anakinra may be helpful in children with secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome, especially patients with underlying systematic juvenile idiopathic arthritis.
Major finding: Initiation of anakinra within 5 days was seen associated with lower mortality (P = .046).
Study details: A retrospective cohort study of 44 children with secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome and several different underlying diseases.
Disclosures: Two coinvestigators reported financial relationships with the maker of the study drug.
Eloseily E et al. Arthritis Rheumatol. 2019 Sep 12. doi: 10.1002/art.41103.
This Week's Must Reads
Must Reads in ALL
Tisagenlecleucel responses persist at 18 months in r/r B-cell ALL, Grupp SA et al. ASH 2018, Abstract 895
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
CAR T-cell cost effectiveness in ALL, Whittington MD et al. JAMA Pediatr. 2018 Oct 8. doi: 10.1001/jamapediatrics.2018.2530
CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9